(Reuters) – Deciphera Pharmaceuticals said on Monday Japan’s Ono Pharmaceutical Co will acquire the cancer drug developer for $2.4 billion in cash.
Ono Pharma has offered $25.60 per share, a premium of 74.7% to the U.S. company’s last closing price of $14.65.
Premarket trading of Deciphera’s shares was currently halted.
The acquisition is expected to close in the third quarter of 2024, Deciphera said.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
